Research programme: collagen I translation inhibitors - Anima Biotech
Latest Information Update: 28 Dec 2024
At a glance
- Originator Anima Biotech
- Class Antifibrotics; Skin disorder therapies; Small molecules
- Mechanism of Action Collagen type I translation inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Fibrosis
- Discontinued Scleroderma
Most Recent Events
- 28 Dec 2024 No recent reports of development identified for research development in Fibrosis in USA
- 02 Dec 2022 Early research is ongoing for Fibrosis in USA (Anima Biotech pipeline, December 2022)
- 02 Dec 2022 Discontinued for Scleroderma in USA (unspecified route) (Anima Biotech pipeline, December 2022)